Research & Innovation
At Dana-Farber/Children’s Hospital Cancer Center, our care is informed by our research. We have a long history of research and innovation in pediatric oncology. Clinical and basic scientists at Boston Children's Hospital and Dana-Farber Cancer Institute are conducting numerous research studies that will help us better understand and treat pediatric cancers.
- We are studying angiogenesis inhibitors, substances that may be able to prevent the growth of tumors.
- We are investigating the use of biological therapies, a wide range of substances that may be able to involve the body's own immune system to fight cancer or lessen harmful side effects of some treatments.
- Researchers are looking into different chemotherapy drugs that may prove effective in children with alveolar soft part sarcoma.
- We are continuously working to reduce the side effects of therapy and determine the optimal treatment strategy for each type of cancer.
Dana-Farber/Children's Hospital Cancer Center is the New England Phase I Center of the Children's Oncology Group. If your child has progressive or recurrent disease, he may be eligible for a number of experimental therapies available through these groups, or through one of our independent clinical investigators.
The Children's Oncology Group is a consortium of cancer treatment centers across the United States, Canada, and other countries that conduct studies of nearly every kind of pediatric cancer. Our participation in the Children’s Oncology Group gives children with cancer unparalleled access to the newest clinical trials.
Read about our innovative research on the Cancer Care Center page.
|Children’s and Dana Farber Cancer Institute are world leaders in opening new avenues of "translational research," bringing laboratory advances to the bedside and doctor's office as quickly as possible. All of our senior medical staff members participate in clinical research activities. Researchers in our Clinical and Translational Investigation Program are working to improve translational research in pediatric oncology.|
|Potential link between cancer and type 2 diabetes|
|George Q. Daley, MD, PhD, director of Stem Cell Transplantation led a study connecting the cancer gene Lin 28 to glucose metabolism which may suggest a relationship between cancer and type 2 diabetes. Read more about this exciting research in the Children’s newsroom.|
|Structural DNA change to reverse hard-to-treat childhood cancer|
|A research team at Boston Children's Hospital and Dana-Farber Cancer Institute collaborated with a biotechnology company to test a new drug that may prevent changes in DNA structure, which can cause a difficult-to-treat form of childhood leukemia. Learn more about this exciting research in the Children’s newsroom.|